Company Perspective and Regulatory Outlook
“We’re committed to building on the established role of Keytruda as a foundational treatment for people with TNBC to provide new options in earlier lines of treatment, in the hope of improving outcomes for people living with this disease,” said Marjorie Green, MD, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “These data support the addition of this TROP2-directed ADC to KEYTRUDA, demonstrating the potential to help people with TNBC and to give doctors another option to treat this disease.”
Merck and Gilead began their collaboration on the ASCENT-04/KEYNOTE-D19 trial in 2021. Currently, Keytruda is approved in the United States and Europe for the treatment of high-risk early-stage TNBC in combination with chemotherapy as a neoadjuvant therapy, and in combination with chemotherapy for locally recurrent unresectable or metastatic TNBC in patients whose tumors express PD-L1.1
References
1. KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC). Merck. May 31, 2025. Accessed June 6, 2025. https://www.merck.com/news/keytruda-pembrolizumab-plus-trodelvy-sacituzumab-govitecan-hziy-reduced-risk-of-disease-progression-or-death-by-35-versus-keytruda-plus-chemotherapy-in-first-line-pd-l1-metastatic-tri/
2. Key Statistics for Breast Cancer. American Cancer Society. Accessed June 6, 2025. https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html